Drug intelligence / Profile preview

MT100

Development stage: Preclinical
Lead developer: Mthera Pharma
Administration: Oral

Overview

MT100 is a preclinical drug candidate being developed by Mthera Pharma for the treatment of rare metabolic diseases. It is developed using Mthera's proprietary Multi-Component Multi-Target (MCMT) technology platform, which focuses on identifying and optimizing synergistic effects of multiple active components to address complex disease pathologies. While the specific molecular targets and the exact modality have not been publicly disclosed, the MCMT platform typically involves complex mixtures designed to address the multi-factorial nature of metabolic disorders.

Targets

SRPX2 (Sushi repeat-containing protein X-linked 2)TEK (Tie2)

Beyond the preview

Go deeper on MT100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT100.

Explore the full profile